X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.indianpharmapost.com/news/shilpa-medicare-launches-pemetrexed-injection-15541
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-jnjs-combination-therapy-patients-with-type-lung-cancer-2024-03-01/
https://investor.lilly.com/news-releases/news-release-details/lillys-retevmor-selpercatinib-first-targeted-therapy-demonstrate
https://www.prnewswire.com/news-releases/lantern-pharma-selects-reprocell-usa-to-provide-support-for-the-phase-2-harmonic-clinical-trial-301812303.html
https://www.ema.europa.eu/en/documents/overview/pemetrexed-baxter-epar-medicine-overview_en.pdf
https://www.biospectrumasia.com/news/25/21608/lotus-acquires-alimta-in-taiwan-from-eli-lilly-for-62-m.html
https://www.globenewswire.com/news-release/2022/09/20/2519421/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Advanced-Non-squamous-Non-Small-Cell-Lung-Cancer.html
https://www.fiercepharma.com/pharma/lillys-new-launches-shine-alimta-drags-sales
https://endpts.com/another-14-generics-threaten-eli-lillys-blockbuster-chemotherapy-alimta/
https://seekingalpha.com/news/3843527-dr-reddys-launches-generic-version-of-cancer-drug-alimta-in-the-us
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211899
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209851
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208696
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204890
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208696
https://www.prnewswire.com/news-releases/innovent-releases-the-orient-31-phase-3-study-first-interim-analysis-results-of-sintilimab-plus-byvasda-bevacizumab-biosimilar-injection-and-chemotherapy-in-patients-with-egfr-mutated-nonsquamous-non-small-cell-lung-cancer-who-p-301429490.html
https://www.fiercepharma.com/pharma/as-lilly-gears-up-for-key-2022-launches-its-existing-meds-post-solid-growth
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203774
https://www.prnewswire.co.uk/news-releases/cantargia-expands-nadunolimab-development-in-non-squamous-nsclc-857354064.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208746
https://www.prnewswire.com/news-releases/innovent-and-lilly-release-clinical-trial-results-of-sintilimab-in-combination-with-alimta-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-nonsquamous-nsclc-in-an-oral-presentation-at-iaslc-wclc-2020-virtual-pr-301108704.html
https://www.businesswire.com/news/home/20200709005757/en/CMS-Establishes-Unique-J-Code-Eagle-Pharmaceuticals%E2%80%99-PEMFEXY%E2%84%A2#:~:text=This%20new%20Healthcare%20Common%20Procedure,PEMFEXY)%2C%2010%20mg).
https://www.prnewswire.com/news-releases/innovent-and-eli-lilly-announce-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-alimta-pemetrexed-and-platinum-as-first-line-therapy-in-non-squamous-nsclc-301045839.html
https://www.prnewswire.com/news-releases/us-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-300979927.html
https://www.businesswire.com/news/home/20191213005464/en/Eagle-Pharmaceuticals-Reaches-Settlement-Agreement-Eli-Lilly
https://www.businesswire.com/news/home/20191016005264/en/Results-STELLAR-Trial-Tumor-Treating-Fields-Chemotherapy/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.reuters.com/article/us-china-health/china-expands-drug-bulk-buy-program-puts-pressure-on-pharma-firms-idUSKCN1VN0QS
https://endpts.com/roches-tecentriq-excels-in-another-lung-cancer-study/
https://www.cnbc.com/2019/08/29/reuters-america-u-s-fda-approves-mylan-generic-of-lilly-lung-cancer-drug-alimta.html
https://www.thepharmaletter.com/article/tentative-approval-of-alimta-generic-sends-mylan-upwards
https://www.patentdocs.org/2019/08/eli-lilly-co-v-hospira-inc-fed-cir-2019.html
https://www.fiercepharma.com/pharma/roche-merck-novartis-and-others-raise-prices-83-meds-to-start-july-analyst?utm_source=internal&utm_medium=rss
https://endpts.com/hansoh-grabs-1b-windfall-in-the-latest-china-pharma-ipo-to-hit-the-hong-kong-exchange/
https://www.fiercebiotech.com/medtech/novocure-nets-approval-for-its-tumor-treating-fields-therapy-mesothelioma
https://www.cnbc.com/2019/04/30/3-major-pharma-companies-just-reported-earning-heres-how-they-did.html
https://endpts.com/with-alimta-patent-cliff-looming-lilly-plots-stronger-foothold-in-frontline-nsclc-with-cyramza/
https://www.prnewswire.com/news-releases/fda-expands-lillys-alimta-pemetrexed-label-with-combination-of-keytruda-pembrolizumab-and-platinum-chemotherapy-for-the-first-line-treatment-of-metastatic-nonsquamous-non-small-cell-lung-cancer-300787242.html
https://endpts.com/new-years-day-price-hikes-on-blockbuster-drugs-set-the-stage-for-a-big-debate/
https://www.biospace.com/article/fd1a-fda-action-alert-merck-insed-and-antares-pharma/
https://www.biospectrumasia.com/news/39/11728/innovent-presents-clinical-data-of-sintilimab.html
http://www.pharmatimes.com/news/ec_green-lights_msds_keytruda_combo_for_lung_cancer_1251811
https://www.fiercepharma.com/manufacturing/fosun-pharma-massively-fakes-api-production-data-and-bribes-regulators-whistle-blower
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617471.htm?utm_campaign=Oncology%20Pembrolizumab%208%2F20%2F2018%20&utm_medium=email&utm_source=Eloqua&elqTrackId=863601bda2b24a2b8502899dc6cdb179&elq=2ea90427c3114c8c955797bf9c7a090e&elqaid=4707&elqat=1&elqCampaignId=3746
Market Place
Share 
